ORMP
Oramed Pharmaceuticals Inc
4.70$
-1.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -4.5% | -7.7% | -9.5% | -10.4% | -5.9% | -5.0% | +9.6% | +36.4% | +4.7% | +16.5% | +37.5% | |
| – | -7.5% | +8.9% | -13.5% | -6.8% | +0.3% | -8.2% | -24.7% | +37.5% | -2.1% | -48.9% | -21.6% | |
| – | +65.6% | +105.1% | +356.3% | -50.3% | +29.3% | +36.9% | -78.8% | +230.3% | -11.9% | -71.3% | +15.5% | |
| – | -7.4% | +9.0% | -13.5% | -6.8% | -0.3% | -8.0% | -25.0% | +37.5% | -6.5% | -47.7% | -23.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -30.2% | -34.2% | -78.7% | +18.5% | +3.9% | -23.0% | +6.0% | +124.2% | +71.3% | -1.8% | +70.7% | |
| – | -31.9% | -36.9% | -88.9% | +41.3% | +7.8% | -3.4% | -32.8% | +65.7% | +211.9% | -44.7% | +1.6% | |
| – | -32.2% | -37.0% | -99.2% | -2.8% | -11.1% | -16.2% | +45.9% | +2.7% | +5.2% | -6.0% | -7.1% | |
| – | -78.5% | +129.9% | +174.9% | +43.4% | -84.2% | -35.5% | +40.5% | -21.7% | -20.9% | +8.6% | -22.2% | |
| – | +9.8% | +1.7% | +6.3% | -11.6% | -6.5% | -3.7% | +9.7% | +31.5% | -1.7% | +19.3% | +33.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -0.2% | +2.9% | +0.1% | -1.7% | -2.4% | +3.3% | +3.3% | +0.4% | -5.4% | +3.8% | +1.3% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.